| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Egholm Michael | President & CEO, Director | C/O STANDARD BIOTOOLS INC., 2 TOWER PLACE, STE 2000, SOUTH SAN FRANCISCO | /s/ Michael Egholm by Tomone Tanaka, Attorney-in-Fact | 27 May 2025 | 0001559779 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | LAB | Common Stock | Sale | $5,126 | -5,116 | -0.19% | $1.00 | 2,746,664 | 22 May 2025 | Direct | F1, F2 |
| Id | Content |
|---|---|
| F1 | The shares were sold to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on March 21, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission ("SEC") on March 24, 2025. |
| F2 | Represents the weighted average sales price per share. The shares sold at prices ranging from $0.9403 to $1.03 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. |